Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) regularly issues news on its RNA interference (RNAi) therapeutics, commercial performance, pipeline progress, and corporate developments. As a company that has led the RNAi field from discovery to approved medicines, its announcements often highlight data from pivotal trials, regulatory milestones, and updates on marketed products such as AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
Investors following ALNY news can expect detailed coverage of clinical results across multiple therapeutic areas, including transthyretin‑mediated amyloidosis (ATTR), hypertension, bleeding disorders, neurological diseases, and metabolic conditions. Recent releases have described post hoc analyses from the HELIOS‑B Phase 3 study of AMVUTTRA in ATTR‑CM and hATTR‑PN, showing effects on gastrointestinal events, cardiac structure and function, and renal outcomes, as well as broader safety and efficacy profiles.
Alnylam’s news flow also includes financial and strategic updates. The company reports quarterly and annual net product revenues, trends in its TTR and rare disease franchises, and guidance associated with frameworks such as its Alnylam P5x25 and Alnylam 2030 strategies. Filings and press releases have discussed convertible senior notes, a revolving credit facility, and partial repurchases of outstanding debt, providing context on capital structure and liquidity.
Operational and manufacturing developments are another key news theme. Alnylam has announced expansion of its Norton, Massachusetts siRNA manufacturing facility and the integration of its siRELIS enzymatic ligation platform, which has been accepted into the FDA’s Emerging Technology Program. Corporate governance items, such as changes to the Board of Directors and executive responsibilities, are also disclosed. For anyone tracking ALNY, this news stream offers insight into clinical milestones, commercial execution, manufacturing scale‑up, and strategic direction in RNAi therapeutics.
Alnylam (Nasdaq: ALNY) reported post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) showing reductions in gastrointestinal (GI) adverse events and reinforcing monotherapy efficacy.
Key findings: a 42% lower GI event rate overall, 37% lower in vutrisiran monotherapy, and 49% lower in patients on tafamidis at baseline; individual symptoms (diarrhea, nausea, vomiting) fell >50% with rate ratios as low as 0.16. A censored monotherapy analysis showed a 32% reduction in the primary composite endpoint through 36 months (HR 0.68; 95% CI 0.49–0.95; p=0.022), consistent with the primary monotherapy HR 0.67 (p=0.016). AMVUTTRA has >8,000 patient‑years exposure and recent approvals in multiple regions.
Alnylam (Nasdaq: ALNY) announced Board changes effective December 2, 2025 and January 5, 2026.
Two directors departed: Mike Bonney stepped down after serving on the Board since 2014 and holding Board Chair roles from December 2015 to August 2021 and Executive Chair from August 2021 to January 2023; Carolyn Bertozzi, Ph.D., resigned from the Board after joining in 2023 and will continue as a scientific advisor following her election to the Eli Lilly board effective December 8, 2025.
New appointment: Stuart Arbuckle will join as an independent director on January 5, 2026; he spent 13 years at Vertex with senior commercial and operating responsibilities and currently serves on the Rhythm Pharmaceuticals board.
Alnylam (Nasdaq: ALNY) presented post hoc HELIOS-B analyses at AHA 2025 showing vutrisiran improved cardiac structure and function and preserved renal function in ATTR-CM patients.
Key imaging findings: CMR showed amyloid regression in 22% of treated patients vs 0% placebo at Year 3; mean ECV change was -0.10% with vutrisiran vs +7.86% with placebo (p=0.006). Renal results: fewer patients had ≥40% eGFR decline (12.7% vs 21.2%) and treatment reduced risk of death and CV events in patients progressing to CKD stage 4+ (HR 0.47; 95% CI 0.26–0.85).
Alnylam (Nasdaq: ALNY) said management will present company overviews at two investor conferences in November 2025:
- UBS Global Healthcare Conference — Monday, November 10, 2025 at 10:15 AM ET in Palm Beach Gardens, Florida
- Jefferies Global Healthcare Conference — Wednesday, November 19, 2025 at 11:30 AM GMT (6:30 AM ET) in London
Live audio webcasts of each presentation will be available on the Investors section of the company website and replays will be posted within 48 hours after each event.
Alnylam (NASDAQ: ALNY) reported Q3 2025 total net product revenues of $851M (103% YoY), driven by TTR revenues of $724M (135% YoY) led by AMVUTTRA. GAAP net income was $251M and non-GAAP net income was $396M for the quarter. The company raised 2025 guidance for the TTR franchise to $2,475M–$2,525M and total net product revenues to $2,950M–$3,050M.
Pipeline progress included HELIOS-B long‑term vutrisiran benefit data, start of ZENITH (zilebesiran) Phase 3 (~11,000 patients) and initiation of TRITON-PN; company reported a $300M Roche milestone and disclosed a U.S. Attorney subpoena related to government price reporting.
Alnylam (Nasdaq: ALNY) will report third-quarter 2025 financial results for the quarter ended September 30, 2025 on Thursday, October 30, 2025 before U.S. markets open.
Management will host a conference call and live audio webcast on October 30, 2025 at 8:30 AM ET to discuss results and outlook. The live webcast will be available on the company’s Investors events page at www.alnylam.com/events, and an archived webcast will be posted approximately two hours after the live event.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has initiated the ZENITH Phase 3 cardiovascular outcomes trial for zilebesiran, dosing its first patient. The global study will evaluate zilebesiran as a biannual treatment for uncontrolled hypertension in approximately 11,000 patients across 35 countries.
The trial will assess zilebesiran's potential to reduce major adverse cardiovascular events in patients with uncontrolled hypertension who have established cardiovascular disease or are at high risk. This milestone has triggered a $300 million payment from partner Roche. Zilebesiran is an RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in the Renin-Angiotensin-Aldosterone System (RAAS), aiming to provide sustained blood pressure control with twice-yearly dosing.
Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) at the HFSA Annual Scientific Meeting 2025. The data showed that vutrisiran treatment led to 37-49% lower rates of gastrointestinal events in ATTR-CM patients compared to placebo.
Key findings include a 42% reduction in GI events in the overall population, with consistent benefits observed across monotherapy and baseline tafamidis groups. For specific symptoms like diarrhea, nausea, and vomiting, reductions of over 50% were observed. A separate analysis demonstrated a statistically significant 32% reduction in the risk of all-cause mortality and recurrent cardiovascular events through 36 months in the monotherapy group.
The study results supported recent approvals of AMVUTTRA for ATTR-CM treatment in multiple regions including the US, EU, and Japan, with over 8,000 patient-years of worldwide experience.
Illumina (NASDAQ: ILMN) and Nashville Biosciences announced that Alnylam Pharmaceuticals (NASDAQ: ALNY) has joined the Alliance for Genomic Discovery (AGD) as its ninth member. Alnylam, specializing in RNA interference therapeutics, will leverage the AGD's clinical genomic database to accelerate drug target discovery.
The partnership will contribute to expanding the database by adding 31,250 new whole-genomes to the existing 250,000 whole-genome cohort. The AGD dataset, completed in March 2025, combines diverse genomic data with longitudinal clinical phenotyping, utilizing Illumina's DRAGEN™ and Connected Analytics platforms for rapid analysis and insights generation.
Alnylam joins existing members including AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk in this collaborative effort to advance therapeutic discoveries, particularly in autoimmune and neurodegenerative diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has priced an upsized private offering of $575 million in 0.00% convertible senior notes due 2028. The offering, increased from the initially announced $500 million, includes an option for purchasers to buy an additional $86.25 million in notes.
The notes will mature on September 15, 2028, with an initial conversion price of $670.11 per share, representing a 40% premium above the reference price. Alnylam entered into capped call transactions to reduce potential dilution and will use approximately $30.7 million of the net proceeds for this purpose.
The company plans to use the remaining proceeds, along with cash on hand, to repurchase approximately $637.8 million of its existing 1.00% convertible senior notes due 2027, with a total repurchase cost of about $1.1 billion including accrued interest.
[ "Successful upsizing of the offering from $500M to $575M indicates strong investor interest", "0.00% interest rate on the new notes reduces interest expense burden", "Capped call transactions help minimize potential dilution for existing shareholders", "Strategic refinancing of existing 2027 notes provides debt restructuring opportunity" ]